Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With < em > KRAS < /em > < sup > G12C < /sup > -Mutated Non-Small Cell Lung Cancer: A Case Series and Literature Review

CONCLUSION: Adagrasib may have a distinct hepatotoxicity profile from sotorasib and is more easily combined with CPIs either sequentially or concurrently. These differences may be used to inform clinical decisions regarding an initial KRASG12C inhibitor for patients who recently discontinued a CPI or experience hepatotoxicity on sotorasib.PMID:38579193 | DOI:10.1200/PO.23.00644
Source: Ann Oncol - Category: Cancer & Oncology Authors: Source Type: research